Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
••
Institut Gustave Roussy1, Université libre de Bruxelles2, Hospital of the University of Pennsylvania3, Swansea University4, University of Paris5, University of California, Los Angeles6, Seoul National University Hospital7, Ludwig Maximilian University of Munich8, Peter MacCallum Cancer Centre9, University of Auvergne10, Memorial Sloan Kettering Cancer Center11, University of California, San Francisco12, Hebron University13, Queen Mary University of London14, Medical University of Vienna15, Harvard University16, The Royal Marsden NHS Foundation Trust17, University of Milan18, Hebrew University of Jerusalem19
289 citations
••
TL;DR: The proposed automated WM lesion segmentation method is the best ranked approach on the MICCAI2008 challenge, outperforming the rest of 60 participant methods when using all the available input modalities, while still in the top‐rank (3rd position) when using only T1‐w and FLAIR modalities.
289 citations
••
University of California, San Francisco1, University of Pennsylvania2, Cleveland Clinic3, Vita-Salute San Raffaele University4, Stony Brook University5, Washington University in St. Louis6, University Hospital of Basel7, Hebron University8, University of Warmia and Mazury in Olsztyn9, University of Münster10, Novartis11, University of Basel12
TL;DR: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide, and this data indicates that this drug should be considered as a second-line treatment for relapsing multiple sclerosis.
Abstract: Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activ...
287 citations
••
TL;DR: Preliminary results from phase I trials in patients with advanced disease and a wide variety of tumour types suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy, particularly in non-small cell lung cancer (NSCLC).
Abstract: ZD1839 (‘lressa’)1,2 is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversible growth inhibition and growth delay in a wide range of tumour cell lines and human tumour xenografts. Moreover, this activity was enhanced when ZD1839 was coadministered with cytotoxic agents. Preliminary results from phase I trials in patients with advanced disease and a wide variety of tumour types suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy, particularly in non-small cell lung cancer (NSCLC). ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC. In addition, further trials are ongoing or planned in a number of other tumour types.
286 citations
••
University of Bologna1, University of Sydney2, Westmead Hospital3, University of Picardie Jules Verne4, University of Lausanne5, Hebron University6, University of Milan7, University Hospital of Lausanne8, National University of Singapore9, Universidade Federal do Rio Grande do Sul10, Vita-Salute San Raffaele University11, University of Insubria12, Barts Health NHS Trust13, Queen Mary University of London14, University of Sassari15
TL;DR: Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or previous tuberculosis from 8 countries show varied clinical profiles.
Abstract: Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or previous tuberculosis from 8 countries show varied clinical profileshttps://bit.ly/369ZGGu
286 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |